From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease

Rizzoli, René; Ricart, Javier; Hernández, B.

doi:10.1016/j.nrleng.2013.12.004

Cited by 6 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding caregiver preference, it has previously been shown in a double blind fashion that caregivers of AD patients prefer the patch over rivastigmine capsules in terms of ease of use, greater satisfaction and less interference with daily life, 14 a finding that was corroborated later in the real-life clinical scenario. 12,15 It is rational to assume that favourable caregiver preference plays a significant role in the all-important compliance to treatment.…”

Section: Discussionmentioning

confidence: 99%

A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch

et al. 2015

View full text Add to dashboard Cite

Objectives:The primary objective of this multicentre, prospective, observational study was to assess whether there is improvement in the patients’ quality of life under treatment with rivastigmine transdermal patch, as it is evaluated both by patients and their caregivers. Compliance to treatment and safety were secondary endpoints.Methods:In total, 1509 patients with mild to moderate Alzheimer’s disease, already treated with rivastigmine transdermal patch 4.6 or 9.5 mg/24 h, were enrolled within a 2.4-month period and prospectively followed up for 2 months on an outpatient basis. The ‘Quality of Life in Alzheimer’s disease (QOL-AD): Patient and Caregiver Report’ questionnaire was used to evaluate quality of life as an effectiveness measure.Results and conclusion:A significant improvement in quality of life, as indicated by a change of 2.7 and 2.5 points in the mean patients’ and caregiver’s QOL-AD: Patient and Caregiver Report score respectively (both p < 0.001) from baseline to end of study was recorded. No serious adverse events were reported. Compliance was high, with 100% compliance reported for almost 9 out of 10 patients at study end.

show abstract

Section: Discussionmentioning

confidence: 99%

A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch

et al. 2015

View full text Add to dashboard Cite

show abstract

“…It is therefore notable that, when questioned in this regard, most (e.g. [70 % [43,44]) caregivers have expressed a preference for patches over capsules [43][44][45][46]. Caregivers have also indicated a reduction in burden, in that patches interfere less with their daily activities [43][44][45][46].…”

Section: Place Of Rivastigmine 133 Mg/24 H Transdermal Patch In the mentioning

confidence: 99%

Rivastigmine Transdermal Patch 13.3 mg/24 h: A Review of Its Use in the Management of Mild to Moderate Alzheimer’s Dementia

Frampton¹

2014

Drugs Aging

View full text Add to dashboard Cite

Rivastigmine is unique among cholinesterase inhibitors commonly used in the treatment of mild to moderate Alzheimer's disease (AD) in that it is available as a transdermal patch formulation (Exelon(®) patch, Rivastach(®) patch, Prometax(®) patch). The patch is applied once daily and, in the EU (and US), is available in three sizes: 5, 10 and 15 cm(2) (releasing 4.6, 9.5 and 13.3 mg rivastigmine/24 h, respectively). In the phase III OPTIMA trial, patients with mild to moderate AD who experienced functional and cognitive decline on the 10 cm(2) patch-the recommended maintenance dose-gained additional benefit when their dose was increased to the 15 cm(2) patch. For example, 15 cm(2) patch recipients showed significantly less functional and cognitive decline than 10 cm(2) patch recipients after 24 weeks of double-blind treatment. Patients receiving the 15 cm(2) patch also showed significantly less functional, but not cognitive, decline than those receiving the 10 cm(2) patch after 48 weeks of double-blind treatment; as such, OPTIMA only met one of its two co-primary endpoints. The 15 cm(2) patch was generally well tolerated; although more 15 cm(2) than 10 cm(2) patch recipients reported adverse events (e.g. nausea and vomiting), fewer 15 cm(2) than 10 cm(2) patch recipients discontinued treatment due to adverse events. By further slowing functional deterioration without markedly compromising tolerability, increasing the transdermal rivastigmine dose to the 15 cm(2) patch has a favourable benefit-risk profile-and therefore represents a valid option-in the treatment of patients with mild to moderate AD who have previously experienced functional and cognitive decline while receiving the 10 cm(2) patch.

show abstract

“…In a literature review, rivastigmine has potential efficacy in AD dementia and less side effects regardless of its administration dose or routes [61]. However, transdermal rivastigmine, especially high transdermal dose, might give more improvement in AD dementia over oral rivastigmine because of the few reported incidents of forgetting doses in case of oral administration [62]. In an open‐label extension study conducted for 24 weeks, there were not any significant clinical side effects while using rivastigmine in both low and high dose of transdermal rivastigmine in patients with mild to moderately severe AD [63].…”

Section: Introductionmentioning

confidence: 99%

The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: A review of recent clinical applications

Eldufani

Blaise

2019

A&D Transl Res & Clin Interv

View full text Add to dashboard Cite

Chronic pain in patients with Alzheimer's disease or dementia is a complex issue in the medical field; these patients suffer from the common causes of chronic pain, especially in geriatric medicine. To ensure the correct type and level of given treatment, medical care should be taken to avoid the contribution of chronic pain and cognitive impairment in the elderly population. Acetylcholinesterase inhibitors (AChE-Is) have been proven as an efficient therapeutic resource for significant improvement in dementia of Alzheimer's disease and chronic pain due to the fact that cholinergic deficit is considered as an early finding in cognitive impairment and persisting pain. Some AChE-Is are investigated here in terms of treatment of dementia and chronic pain management. Neostigmine has been used as an adjunct analgesic in the postoperative period and in combination with other analgesic medications in an intrathecal approach. Rivastigmine has, over the past ten years, become the approved agent for the management of dementia of mild to moderate Alzheimer's disease and has gained approval for treating different types of non-Alzheimer's dementia. In this review, we will focus on the two types of AChE-Is (rivastigmine and neostigmine) in the development of their clinical use and their respective mechanisms of actions on improving cognitive function and managing chronic pain.

show abstract

From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease

Cited by 6 publications

References 23 publications

A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch

A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch

Rivastigmine Transdermal Patch 13.3 mg/24 h: A Review of Its Use in the Management of Mild to Moderate Alzheimer’s Dementia

The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: A review of recent clinical applications

Contact Info

Product

Resources

About